Calamos Wealth Management LLC Acquires New Position in Integra LifeSciences Holdings Corporation $IART

Calamos Wealth Management LLC bought a new position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor bought 30,171 shares of the life sciences company’s stock, valued at approximately $284,000.

A number of other hedge funds also recently added to or reduced their stakes in IART. Global Retirement Partners LLC purchased a new position in Integra LifeSciences in the 4th quarter valued at approximately $25,000. Osaic Holdings Inc. raised its stake in shares of Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after acquiring an additional 1,104 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Integra LifeSciences by 145.9% in the fourth quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock valued at $78,000 after acquiring an additional 3,742 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in Integra LifeSciences by 595.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after purchasing an additional 6,814 shares during the period. Finally, Virtu Financial LLC purchased a new position in Integra LifeSciences in the fourth quarter valued at $124,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on IART. Truist Financial cut their price target on Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating on the stock in a report on Wednesday, April 15th. BMO Capital Markets initiated coverage on Integra LifeSciences in a research report on Wednesday, July 8th. They set a “market perform” rating and a $19.00 price objective for the company. Weiss Ratings upgraded shares of Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. Wells Fargo & Company raised their target price on shares of Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. Finally, Wall Street Zen upgraded shares of Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 13th. One analyst has rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Integra LifeSciences has a consensus rating of “Reduce” and a consensus target price of $17.17.

Integra LifeSciences Stock Performance

Shares of Integra LifeSciences stock opened at $18.78 on Thursday. The firm’s fifty day simple moving average is $16.68 and its 200-day simple moving average is $12.98. Integra LifeSciences Holdings Corporation has a 12 month low of $8.70 and a 12 month high of $19.13. The stock has a market capitalization of $1.46 billion, a price-to-earnings ratio of -2.91, a PEG ratio of 1.27 and a beta of 1.22. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.38 and a quick ratio of 1.95.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.13. The firm had revenue of $391.92 million during the quarter, compared to analysts’ expectations of $381.81 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. Integra LifeSciences’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.41 EPS. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. As a group, equities analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.